Targets

STAT3 / STAT6

9 articles

Industry NewsValo Health / Montai TherapeuticsFierce Biotech

Flagship merges AI biotechs Valo and Montai under the Valo name

  • Valo Health and Montai Therapeutics, both Flagship Pioneering companies, are combining; the merged company will keep the Valo name and terms were not disclosed.
  • Valo CEO Brian Alexander continues to lead; Montai CEO Margo Georgiadis stays on as an advisor.
  • The pipeline is led by Montai's MTAI-1025 and an oral STAT6 inhibitor for atopic dermatitis, and existing partnerships, including Montai's Pfizer deal, are to continue.
PointsBased on public reports

Merging two sister companies is a quiet admission that a platform story alone no longer funds itself; the combined entity pairs Valo's human-data biology with Montai's chemistry and clinical assets. An oral STAT6 inhibitor is a crowded bet against injectable biologics in atopic dermatitis, so the merged company will be judged on that asset's data, not on the AI narrative. Undisclosed terms leave runway the main unknown.

PharmacologyBritish Journal of Pharmacology

Triptonide curbs macrophage glycolysis to ease sepsis-related lung injury

  • Triptonide, a diterpenoid from Tripterygium wilfordii, was tested in mouse endotoxemia and caecal ligation and puncture models of sepsis-associated lung injury.
  • It limited macrophage pro-inflammatory activation, reduced lung inflammation, oedema and apoptosis, and improved survival.
  • Transcriptomic and metabolic analyses showed suppressed aerobic glycolysis in inflammatory macrophages, via the STAT3/HIF-1α axis.
PointsBased on the abstract

Triptonide is a notoriously narrow-window Tripterygium compound, so I'd want the therapeutic index before any mechanism claim. Dosing after CLP onset, not just pre-treatment, plus a STAT3 or HIF-1α rescue to prove the axis is causal, would tell me far more. Glycolysis suppression in macrophages also risks blunting host defence against the infection itself.

Industry NewsSanofi / Nurix TherapeuticsBioPharma Dive

Sanofi Drops Nurix's Oral STAT6 Degrader After New Nonclinical Eczema Findings

  • Sanofi has discontinued SAR448272, the oral STAT6 degrader it licensed from Nurix; Sanofi pointed to new nonclinical findings in eczema models and said it still values the STAT6 pathway.
  • The 2020 collaboration carried $55 million upfront and up to $2.5 billion in potential payments; Sanofi exercised its option last year and paid a $10 million milestone when Phase 1 began in August.
  • Nurix shares fell more than 40%, though analysts said its lead asset, bexobrutideg (partnered with Roche), is unaffected.
PointsBased on public reports

Nobody outside the two companies can say what the nonclinical signal was, which is the real problem: a safety or tolerability finding in a degrader would rewrite the read-across, while a molecule-specific flaw would not. Kymera's STAT6 degrader, with a mid-stage readout due, is now the class test, and Sanofi's second STAT6 programme with Recludix shows it is not walking away from the target. Watch whether Nurix retains rights.

PharmacologyBiochemical Pharmacology

Natural-product-derived β-carboline D14 curbs glioma by inhibiting SRC

  • Starting from a plant alkaloid with known antitumor activity, the authors built a scalable total synthesis and made a series of nineteen analogues; D14 was the most cytotoxic across glioma lines, including patient-derived primary cells.
  • Computational screening, dynamics and thermal-shift assays pointed to SRC as the target, with binding near Gln147 and reduced SRC phosphorylation, dampening PI3K/AKT and STAT3 signaling.
  • In an orthotopic mouse glioma model, D14 slowed tumor growth without evident organ toxicity.
PointsBased on the abstract

Nineteen analogues, one winner, and a target call resting mostly on docking, dynamics and a thermal shift: I wouldn't call SRC the mechanism yet. Without kinome selectivity and a Gln147 mutant, this could be polypharmacology. And orthotopic GL261 is forgiving; show brain exposure across the BBB and a real margin over the cytotoxic dose.

Medicinal ChemistryACS Medicinal Chemistry Letters

Belharra's benzimidazoles aim to inhibit STAT6 directly, downstream of IL-4/IL-13

  • This patent highlight describes substituted benzimidazoles from Belharra Therapeutics that directly inhibit STAT6.
  • STAT6 relays IL-4 and IL-13 signaling into type 2 inflammatory programs behind allergic disease.
  • Compounds show submicromolar biochemical activity, pointing to possible oral, pathway-focused alternatives to extracellular IL-4/IL-13 biologics.
PointsBased on the abstract

Transcription factors are the hard end of tractability, so a patent that credibly shows direct STAT6 engagement is worth tracking even at submicromolar potency. Biochemical activity is the easy half; whether these compounds reach cellular target engagement and avoid other STATs is what decides it. The comparison to dupilumab-class biologics is a long way off.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Oral non-peptide STAT6 degrader WW-210 eases atopic dermatitis in mice

  • Replaces the earlier phosphopeptide-based STAT6 PROTAC with non-peptide degraders designed for oral dosing.
  • WW-210 degraded STAT6 at very low concentrations with a wide selectivity window over other STAT family members.
  • It showed measurable oral bioavailability and degraded STAT6 in blood and spleen; in an atopic dermatitis mouse model it eased skin lesions, lowered serum IgE and reduced mast cell infiltration.
PointsBased on the abstract

STAT6 is a transcription factor with a flat, polar SH2 surface, exactly the kind of target where inhibitors struggle and degraders can sidestep the problem. Getting oral exposure from a PROTAC that started life as a phosphopeptide is the real achievement; I'd like to see how molecular weight and polarity were managed, and whether the STAT-family selectivity holds in primary T cells.

Computational & AIJournal of Medicinal Chemistry (ACS)

AI Pocket-Based Design Yields a Potent STAT3 Inhibitor for Colorectal Cancer

  • A pocket-conditioned, autoregressive generative AI model was used to design candidate molecules directly within the STAT3 binding pocket, rather than screening pre-existing compound libraries.
  • This structure-based generative approach produced a potent small-molecule STAT3 inhibitor that advanced to biological evaluation.
  • The inhibitor showed activity against colorectal cancer, where STAT3 hyperactivation is a recognized driver of tumor growth and survival.
PointsBased on the abstract

STAT3's SH2 dimerization pocket is shallow and dynamic — the reason most inhibitor programs (niclosamide analogs, peptidomimetics) never reached clinic. Generating atoms directly inside that pocket geometry, rather than rescoring a static virtual library, is the real methodological jump here. Still, "potent" on paper means little until we see SH2 selectivity over STAT1/5 and a synthesizable route — that's where de novo hits usually stall.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Oral PROTAC Degrader Targets STAT6 in Atopic Dermatitis

  • A new PROTAC degrader targets STAT6, the transcription factor that carries IL-4/IL-13 signals driving Th2-type allergic inflammation.
  • Instead of inhibiting STAT6, the molecule links a STAT6-binding fragment to a degradation handle for potency and selectivity over related STAT proteins.
  • It reportedly showed oral efficacy in preclinical models, pointing to a pill-based alternative to injectable biologics for atopic dermatitis.
PointsBased on the abstract

Oral bioavailability is the harder win here than target choice — PROTACs routinely blow past Lipinski/bRo5 limits (MW, PSA), so a gut-stable, orally efficacious degrader is the rarer synthetic feat. If STAT1/3/5 selectivity holds up in vivo, this leapfrogs injectable dupilumab and pressures other oral STAT6 degrader programs already in the clinic.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Novel TRPM7 Inhibitors Curb Breast Cancer Growth and Invasion in Preclinical Models

  • Building on the TRPM7 blocker NS8593, researchers created a set of 2-aminobenzimidazole analogues and identified two standout leads, SDUY212 and SDUY225, validated by electrophysiological recordings.
  • Both compounds slowed growth, migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells and triggered apoptosis and cell-cycle arrest; SDUY212 also shrank tumors in xenograft-bearing mice.
  • The anti-invasive effect appeared linked to reduced EGF-triggered STAT3 activation downstream of TRPM7.
PointsBased on the abstract

Actually running electrophysiology on the leads, not just IC50s from a fluorescence assay, is what makes me trust this series — ion channel hits die in droves from off-target and assay artifacts. Still, I'd want a TRPM6/TRPM8 selectivity panel before calling SDUY212 a real chemical probe; TRPM7 has essentially none, and the 2-aminobenzimidazole scaffold looks synthetically forgiving enough to actually chase that SAR.